Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H38N4O4S |
Molecular Weight | 574.734 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC3=CC=CC=C3)\C=C\S(=O)(=O)C4=CC=CC=C4
InChI
InChIKey=RHJLQMVZXQKJKB-FPHSVDBKSA-N
InChI=1S/C32H38N4O4S/c1-35-20-22-36(23-21-35)32(38)34-30(25-27-13-7-3-8-14-27)31(37)33-28(18-17-26-11-5-2-6-12-26)19-24-41(39,40)29-15-9-4-10-16-29/h2-16,19,24,28,30H,17-18,20-23,25H2,1H3,(H,33,37)(H,34,38)/b24-19+/t28-,30-/m0/s1
Molecular Formula | C32H38N4O4S |
Molecular Weight | 574.734 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
APC-3316 is a vinyl sulfone cystein protease inhibitor. It is a potent, irreversible cysteine protease inhibitor and a potent and selective CCR4 antagonist. Its therapeutic targets are cruzain, a cysteine protease of the protozoan parasite Trypanosoma cruzi, and cathepsins B and L, which are associated with cancer progression. It was discontinued after preclinical trials in Chagas disease in USA.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P25779 Gene ID: NA Gene Symbol: NA Target Organism: Trypanosoma cruzi Sources: https://adisinsight.springer.com/drugs/800016956 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:09:34 GMT 2023
by
admin
on
Sat Dec 16 08:09:34 GMT 2023
|
Record UNII |
320A4L58IZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
550316
Created by
admin on Sat Dec 16 08:09:34 GMT 2023 , Edited by admin on Sat Dec 16 08:09:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID401101718
Created by
admin on Sat Dec 16 08:09:34 GMT 2023 , Edited by admin on Sat Dec 16 08:09:34 GMT 2023
|
PRIMARY | |||
|
502960-90-9
Created by
admin on Sat Dec 16 08:09:34 GMT 2023 , Edited by admin on Sat Dec 16 08:09:34 GMT 2023
|
PRIMARY | |||
|
233277-99-1
Created by
admin on Sat Dec 16 08:09:34 GMT 2023 , Edited by admin on Sat Dec 16 08:09:34 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
9851116
Created by
admin on Sat Dec 16 08:09:34 GMT 2023 , Edited by admin on Sat Dec 16 08:09:34 GMT 2023
|
PRIMARY | |||
|
320A4L58IZ
Created by
admin on Sat Dec 16 08:09:34 GMT 2023 , Edited by admin on Sat Dec 16 08:09:34 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|